...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A motif in LILRB2 critical for Angptl2 binding and activation
【24h】

A motif in LILRB2 critical for Angptl2 binding and activation

机译:LILRB2中的一个基序对Angptl2的结合和激活至关重要

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A better understanding of the interaction between extrinsic factors and surface receptors on stem cells will greatly benefit stemcell research and applications. Recently, we showed that several angiopoietin-like proteins (Angptls) bind and activate the immune inhibitory receptor human leukocyte immunoglobulin (Ig)-like receptor B2 (LILRB2) to support ex vivo expansion of hematopoietic stem cells (HSCs) and leukemia development. However, the molecular basis for the interaction between Angptls and LILRB2 was unclear. Here, we demonstrate that Angptl2 expressed in mammalian cells forms high-molecular- weight species and that ligand multimerization is required for activation of LILRB2 for downstream signaling. A novel motif in the first and fourth Ig domains of LILRB2 was identified that is necessary for the receptor to be bound and activated by Angptl2. The binding ofAngptl2 to LILRB2 is more potent than and not completely overlapped with the binding of another ligand, HLA-G. Immobilized anti-LILRB2 antibodies induce a more potent activation of LILRB2 than Angptl2, and we developed a serum-free culture containing defined cytokines and immobilized anti-LILRB2 that supports a net expansion of repopulating human cord blood HSCs. Our elucidation of the mode of Angptl binding to LILRB2 enabled the development of a new approach for ex vivo expansion of human HSCs.
机译:更好地了解外在因素与干细胞表面受体之间的相互作用将极大地有利于干细胞的研究和应用。最近,我们显示了几种血管生成素样蛋白(Angptls)结合并激活免疫抑制受体人类白细胞免疫球蛋白(Ig)样受体B2(LILRB2),以支持造血干细胞(HSCs)的体外扩增和白血病的发展。但是,Angptls和LILRB2之间相互作用的分子基础尚不清楚。在这里,我们证明在哺乳动物细胞中表达的Angptl2形成高分子量物种,并且配体多聚化是激活LILRB2下游信号传递所必需的。鉴定了LILRB2的第一和第四Ig结构域中的新基序,该基序对于受体被Angptl2结合和激活是必需的。 Angptl2与LILRB2的结合比另一种配体HLA-G的结合更有效,并且不完全重叠。固定化的抗LILRB2抗体比Angptl2诱导更有效的LILRB2激活,我们开发了一种无血清培养物,其中包含确定的细胞因子和固定化的抗LILRB2,可支持人脐带血HSC的净扩增。我们对Angptl与LILRB2结合的模式的阐明使得能够开发用于人HSC的离体扩增的新方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号